奥瑞克制药
ORIC
12.35
-0.42
-3.29%
奥瑞克制药
US · ORIC
#3089 按市值排名
上市于 2020
12.35
-0.42
-3.29%
实时 - 追踪5344个代码 - 心跳于494秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期(2026/Q3)披露持股的机构数量减少了1家。
- 机构持股总比例下降了2.7个百分点。
机构持股
- 机构持股比例
- 120.01% -2.68pp
- 机构数量
- 207 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份,同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund42.60%
Hedge Fund38.73%
VC/PE Fund31.52%
Public Company4.97%
Individual/Insider1.04%
Family Office/Trust0.99%
Private Company0.93%
Government Pension Fund0.16%
主要股东 截至 2026-06-30
Nextech Invest Ltd.
6.91% · 7.16M 股
BlackRock
6.58% · 6.82M 股
EcoR1 Capital, LLC
6.49% · 6.73M 股
T. Rowe Price Group, Inc.
6.38% · 6.62M 股
Viking Global Investors LP
4.95% · 5.13M 股
State Street Global Advisors
4.72% · 4.89M 股
SR One Capital Management, LP
4.45% · 4.62M 股
Vanguard Capital Management, LLC
4.36% · 4.52M 股
VR Management, LLC
4.17% · 4.32M 股
New Enterprise Associates, Inc.
3.97% · 4.12M 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 26次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Jacob Chacko | Chief Executive Officer | 0.56% |
| Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 0.24% |
| Lori Kunkel | Independent Director | 0.08% |
| Dominic Piscitelli | Chief Financial Officer | 0.07% |
| Pratik Multani | Chief Medical Officer | 0.07% |
| Angie You | Independent Director | 0.03% |
| Mardi Dier | Independent Director | -- |
| Steven Hoerter | Indepdnent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Automatic Disposition | -3,200 | $12.91 |
| 2026-09-30 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Derivative Exercise and Sale | -3,500 | $1.60–12.91 |
| 2026-09-27 | Dominic Piscitelli | Chief Financial Officer | Derivative Exercise and Sale | -13,400 | $4.36–13.53 |
| 2026-09-23 | Dominic Piscitelli | Chief Financial Officer | Derivative Exercise and Sale | -600 | $4.36–13.51 |
| 2026-08-25 | Dominic Piscitelli | Chief Financial Officer | Derivative Exercise and Sale | -77,000 | $4.36–13.69 |
| 2026-07-23 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Open Market Disposition | -9,600 | $12.02 |
| 2026-07-23 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Derivative Exercise and Sale | -3,500 | $1.60–12.02 |
| 2026-07-05 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Automatic Disposition | -300 | $12.00 |
| 2026-02-23 | Dominic Piscitelli | Chief Financial Officer | Derivative Exercise and Sale | -52,000 | $4.36–13.51 |
| 2026-01-15 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Automatic Disposition | -6,700 | $12.00 |
| 2026-01-01 | Pratik Multani | Chief Medical Officer | Other Derivative Acquisition | +35,500 | -- |
| 2026-01-01 | Pratik Multani | Chief Medical Officer | Other Derivative Acquisition | +214,000 | $8.17 |
| 2026-01-01 | Angie You | Independent Director | Other Derivative Acquisition | +40,000 | $8.17 |
| 2026-01-01 | Richard Heyman | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | Other Derivative Acquisition | +40,000 | $8.17 |
| 2026-01-01 | Lori Kunkel | Independent Director | Other Derivative Acquisition | +40,000 | $8.17 |
| 2026-01-01 | Mardi Dier | Independent Director | Other Derivative Acquisition | +40,000 | $8.17 |
| 2026-01-01 | Jacob Chacko | Chief Executive Officer | Other Derivative Acquisition | +112,500 | -- |
| 2026-01-01 | Jacob Chacko | Chief Executive Officer | Other Derivative Acquisition | +675,000 | $8.17 |
| 2026-01-01 | Steven Hoerter | Indepdnent Director | Other Derivative Acquisition | +40,000 | $8.17 |
| 2026-01-01 | Dominic Piscitelli | Chief Financial Officer | Other Derivative Acquisition | +34,500 | -- |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
奥瑞克制药 讨论区 0 条评论